CFO of Protagonist Therapeutics (PTGX) sells 8,588 shares

Rhea-AI Filing Summary

Protagonist Therapeutics Chief Financial Officer Asif Ali reported a sale of common stock in a Form 4 filing. On January 20, 2026, he sold 8,588 shares of Protagonist Therapeutics common stock at a price of $82.48 per share. According to the footnote, the sale was made to cover tax withholding obligations incurred when restricted stock units settled, meaning it was connected to equity compensation rather than a discretionary open-market sale. After this transaction, Ali beneficially owns 78,077 shares of the company’s common stock directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ali Asif

(Last) (First) (Middle)

C/O PROTAGONIST THERAPEUTICS, INC.

7707 GATEWAY BLVD., SUITE 140

(Street)

NEWARK CA 94560-1160

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Protagonist Therapeutics, Inc [ PTGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/20/2026		S		8,588(1)	D	$82.48	78,077	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units.

	/s/ Matthew Gosling, Attorney-in-Fact for Asif Ali	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PTGX report in this Form 4?

The filing shows that Chief Financial Officer Asif Ali sold 8,588 shares of Protagonist Therapeutics common stock on January 20, 2026 at $82.48 per share.

Why did Protagonist Therapeutics (PTGX) CFO Asif Ali sell shares?

The footnote states the sale was to cover tax withholding obligations incurred upon the settlement of restricted stock units, tying the transaction to equity compensation.

How many PTGX shares does the CFO own after this transaction?

Following the reported sale, Asif Ali beneficially owns 78,077 shares of Protagonist Therapeutics common stock in direct ownership.

Was the PTGX CFO’s Form 4 transaction direct or through another entity?

The transaction is reported as direct ownership (D), and there is no indication in the footnotes that the shares are held through another entity or that beneficial ownership is disclaimed.

What type of security did the PTGX insider transaction involve?

The transaction involved Protagonist Therapeutics common stock, classified as a non-derivative security in the filing.

What role does Asif Ali hold at Protagonist Therapeutics (PTGX)?

Asif Ali is identified in the filing as an officer of Protagonist Therapeutics, serving as the company’s Chief Financial Officer.